We engineerand manufactureplatelets.
Inspired by platelet biology to save lives
HemostOD's technology platform unlocks the power of platelets in:
Thrombocytopenia
lead program 1Developing universal* platelets for treatment in patients with, or at risk of, HLA immune-refractoriness.
Tissue-targeted cargo delivery
lead program 2Using our unique CAR-PLT* technology for shielded delivery of miRNA/siRNA or proteins to specific target tissues.
Regenerative medicine
Using engineered platelets in wound healing, anti-inflammatory and immunomodulating applications.
Culture of therapeutic stem cells
Using platelet lysate produced from our universal platelets to boost cell proliferation.
* engineered to be HLA-low
HemostOD: a swiss-based preclinical company
Founded in 2020, HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland.
We are a preclinical stage company developing applications based on our proprietary platform to engineer and manufacture universal platelets.
A unique & scalable
platelet manufacturing
platform
Inspired by the physiological generation of platelets in the bone marrow, HemostOD has developed an innovative solution to manufacture engineered platelets, thereby providing a practically unlimited source of universal platelets.
Our unique process integrates molecular & cell biology techniques to build a stable megakaryocitic cell line (steps 1, 2 & 3), followed by the use of advanced microfluidic technologies in a bioreactor to fragment megakaryocytes into platelets (step 4). This robust and rapid process enables the generation of large quantities of homogeneous and high-quality platelets in a few hours.
Our IP-protected platform includes:
Immortalization of hematopoietic progenitors (stem) cells from a single donor.
Engineering of cells to introduce custom features, modifying the platelet surface and/or content for controlled release.
Differentiation into a practically unlimited source of megakaryocytes, the platelet progenitor cells.
Ex-vivo generation of platelets in a robust, fast and scalable manufacturing process.
Partnering opportunities
We are open to collaborations and welcome enquiries about partnership opportunities for applications in all our target areas:
- Thrombocytopenia
- Tissue-targeted cargo delivery technology (CAR-PLT*)
- Regenerative medicine
- Culture of therapeutic stem cells (platelet lysate)
- and beyond.
For enquiries, please contact:
contact@hemostod.com
Latest news
Stay updated with our latest developments and milestones
HemostOD secures a CHF 4.3M seed extension round
The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors.
HemostOD appoints an International Scientific Advisory Board
HemostOD is proud to present the profiles of our distinguished scientific advisors.
HemostOD receives a FIT Tech Growth loan
HemostOD received the support of the "Fondation pour l'Innovation Technologique" (FIT) in the form of a CHF 500'000 loan: the FIT Tech Growth.
HemostOD partners with the biggest transfusion service in Switzerland
The Swiss preclinical biotech company HemostOD and Interregional Blood Transfusion SRC are pleased to announce their partnership to collaborate on the in vitro production of platelets.
HemostOD enters EIT Health's Gold Track Programme
HemostOD has been recognized as a promising healthcare company by a jury of experts. The team will now receive tailored support to grow the company.
Partnering with the Swiss Biotech Center
HemostOD partners with the Swiss Biotech Center to pre-industrialize its technology.
Our partners
Join us
We do not have any open positions at the moment, but we are always happy to hear from interested talents. Please reach out to us by email at the address below.